Needham & Co initiates coverage on PDL BioPharma Inc. (Nasdaq: PDLI) with a Buy rating and $27 price target.

This article: 116 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE